Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Paul S. who wrote (321)	3/30/1998 2:20:00 PM
From: Jon Smith	Respond to of 1185

This was posted on stockhouse. Its from the Mini Cap Analyst. <<Nortran's Board of Directors has now given the reins to Mr. Bob Rieder. Mr. Rieder has worn many different hats in his career. In the last decade he has been a venture capitalist, the last four of which he spent with Canada's leading firm in VC funding of life sciences, MDS Capital Corp. This division of MDS Inc. (Toronto Stock Exchange: MHG.B $32.90), which is a diversified healthcare company, manages a fund exceeding Cdn $500 million. Mr. Rieder was Vice President of MDS Ventures Pacific Inc., a division of MDS Capital Corp. In this capacity he has been exposed to many hundreds of biotech companies and intensely scrutinized dozens of these. MDS Capital has a very hands-on approach to its venture funding. In fulfilling this approach, Mr. Rieder has had the benefit of working closely with and holding multiple directorships with MDS investee companies. Among these are early stage companies such as Stressgen Biotechnologies (Toronto Stock Exchange: SSB $2.57) and Micrologix Biotech (Toronto Stock Exchange: MBI $3.45). He has also played the role of acting CEO with another of MDS' investee companies. Mr. Rieder consequently arrives at Nortran with substantial strategic insight as well as hands-on management experience pertaining to the corporate development of junior biotech companies. In his own words, Mr. Rieder noted, "I have a clear idea of what is required for success." One of the things he emphasized was his commitment to maximizing shareholder value. He noted that in a company with out sales, the customer is the investor. Investors are the source of capital that provides the basis for success, and appropriate energy will be directed to this customer.>> I really like the sound of this guy. Especially how he understands that we the investor need to be rewarded. Good day all! Jon

To: Paul S. who wrote (321)	3/30/1998 3:46:00 PM
From: Casey	Respond to of 1185

Paul: <<If Maedels specialty is the junior resource market, then I am not at all suprised that his stock picks have not performed. Show me a resource letter writer that has had success. >> Fwiw, Maedel's recommends a whole range of mini-cap stocks, including tech stocks and biotechs. He recommended IZP as a buy when it was above $3.00. His tech plays are particularly battered. What was unpleasant was when his plays did not pan out, he sidestepped the problem in his newsletter, or left it hanging. Faxes and emails to his service never yield an answer. I suggest you get a sample copy of his recent newsletter and take a look at his recommendation list. It's not pretty.